A New Experimental Model of Transient and Short-lasting Muscle Pain in Humans Based on Diathermy

August 29, 2018 updated by: José Biurrun Manresa, National Council of Scientific and Technical Research, Argentina

A New Experimental Model of Acute Muscle Pain in Humans Based on Short-wave Diathermy

This study evaluates the use of short-wave diathermy (SWD) as an novel experimental model to induce transient and intensity-controlled muscle pain by heating muscle tissue.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Application of short-wave diathermy All researchers, students and postdocs involved in experimental application of SWD will be properly trained by the Non-Ionizing Radiation Research Group of the National University of Entre Ríos. The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit (CEC Electrónica, Córdoba, Argentina). The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes. In case the volunteer feels excessive discomfort or does not adequately tolerate the application of SWD, the device will be turned off immediately and the experimental session will finish.

Experimental pain model assessment

  • Model direct effects: maximum and average pain ratings will be assessed through a Visual Analog Scale (VAS). The VAS ranges from 0 to 10, where 0 represents no perception, 3 represents the pain threshold (i.e. the minimum irradiation intensity that elicits pain) and 10 represents the tolerance threshold (i.e. the irradiation intensity that elicits an intolerable pain sensation). Duration of pain will also be recorded, in case the experiment has to be interrupted before SWD application is completed and to assess potential cases in which pain outlasts SWD application. Furthermore, delivered RF power will be measured using a Bird 43 RF wattmeter (Bird Technologies, OH, USA).
  • Pressure stimulation: pressure stimulation will be applied through a Somedic algometer (Somedic SenseLab AB, Sweden), directly over the muscle being examined, using a 1 cm2 round tip. Pressure will be gradually increased from 0 kPA until a maximum of 1000 kPa at a rate of approximately 30 kPa/s. Pressure pain threshold (PPT) will be defined as the force at which the pressure sensation becomes painful. Pressure tolerance threshold (PTT) will be defined as the force at which pressure sensation becomes intolerable. If any of the threshold are not reached until the pressure is increased to 1000 kPa, the this value will be considered as the corresponding threshold.
  • Pinprick and tactile stimulation: pinprick stimuli will be applied on the skin over the muscle being examined using a set of pinprick stimulators, consisting on a needle with a 0.25 mm tip linked to calibrated weights, ranging from 1 g to 50 g, in order to apply forces between 8 and 500 mN approximately. Dynamic tactile stimulation will be applied by stroking a cotton tip over the skin. Pinprick sensitivity (PS) and dynamic tactile sensitivity (DTS) will be quantified using the VAS described above.
  • Electrical stimulation: electrical stimuli will be applied to the skin over the muscle being examined using a concentric electrode, in which the cathode is made of 16 stainless steel blunt pins with 0.2 mm diameter tips and 1 mm length, and the anode is a concentric stainless steel ring of 20 mm diameter. The electrical stimulus will consist on a rectangular pulse of 1 ms duration, generated by a Biopac STMISOLA constant-current electrical stimulator (Biopac Systems Inc., California, USA). Stimulation intensity will be increased from 1 mA in steps of 0.5 mA until a pain sensation is evoked. This intensity will be defined as the electrical pain threshold (EPT). Once the EPT is determined, repeated stimulation will be applied referenced to this intensity in order to record somatosensory evoked potentials (SEPs) through surface electroencephalography (EEG).
  • Motor responses: motor responses will be recorded from upper and lower limbs. For the upper limb, two sets of experimental motor tasks are planned, and the overall aim is to measure changes in precision in the execution of the motor tasks due to pain. The first one will be a simple task, basically consisting on the use of a joystick to move a cursor to a two-dimensional moving target displayed in a computer screen. Specific details of the implementation of the optimal setup for this motor task and the required software will be provided by collaborators from the Physiology of Action Lab at Universidad de Buenos Aires. The second motor task will involve more complex movements and haptic feedback, provided by a Phantom Omni haptic device (SensAble Technologies, Inc., Massachusetts, USA). The haptic device can provide controlled levels of force feedback (up to 3.3 N) and a precise mapping of the trajectories employed in the motor task in three dimensions (resolution: 0.055 mm). Specific details of the implementation of the optimal setup for this motor task and the required software will be provided by collaborators from the Robotics Research Group at National University of Entre Ríos. For the lower limb, the motor task will consist on a balance task performed over high-resolution pressure sensing platform that will be able to record differences in weight loading between left and right leg and variations in the center of pressure (CoP). The platform is a recent technological development from the Electronic Prototyping and 3D Printing Lab at the Faculty of Engineering of National University of Entre Ríos, and it has a sensing area of 430 x 320 mm, with a resolution of 4 pressure sensors per cm2 and a measurement range from 1 to 785 kPa.
  • Brain responses: EEG will be recorded using a Neuroscan SynAmps amplifier (Compumedics Ltd., Victoria, Australia) during the planning and execution of motor tasks, in order to evaluate changes in movement-related cortical potentials (MRCP) in relation to SWD-induced pain (Jochumsen et al. 2015). Additionally, resting-state EEG will be recorded before, during and after SWD application, in order to assess potential changes in functional connectivity (FC) (Mayhew et al. 2013). FC analysis will be performed by collaborators from CNAP at Aalborg University.

Sample size considerations

The experimental design is an interventional, pre-post study design (Thiese 2014), in which each participant acts as his own control. Sample size calculation will be performed taking into account the expected effect size that the model will have on the primary outcome (PPT). Several experiments have shown that PPT in the wrist extensor/flexor muscles (e.g. extensor carpi radialis longus) is around 350 ± 150 kPa (mean ± standard deviation), whereas PPT for the ankle dorsiflexor muscles (e.g. tibialis anterior) is around 600 ± 250 kPa (Fischer 1987; Delfa de la Morena et al. 2013). On the other hand, there is no existing information on the expected size of the difference in PPT due to the application of SWD, so this value will be approximated taking into account reference values of differences in PPT generated by other experimental models of pain, such as the injection of hypertonic saline solution or delayed onset muscle soreness. In these cases, PPT is usually reduced between 10 and 30% during the effects of the model, so an average of 20% difference will be considered in order to calculate the sample size for these experiments. Considering a probability of making a type I error (α) of 5%, a statistical power (1 - β) of 80%, and an estimated correlation between measures of 0.8, the sample size required to detect the aforementioned difference is 16 volunteers for the experiment in the upper limb and 17 volunteers for the experiment in the lower limb. In order to account for an unexpectedly larger variation, 20 subjects are expected to be recruited for each experiment.

Study Type

Interventional

Enrollment (Actual)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Entre Ríos
      • Oro Verde, Entre Ríos, Argentina, 3100
        • Facultad de Ingeniería - Universidad Nacional de Entre Ríos (Argentina)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Understanding of the content and scope of the experiment, and compliance with the experiment's instructions.
  • To have signed the informed consent.

Exclusion Criteria:

  • Pregnancy.
  • Previous history of neurological or musculoskeletal disorders or chronic pain.
  • Previous history of addictive behavior, defined as abuse of alcohol, cannabis, opioids or other drugs.
  • Previous history of thermosensitivity disorders.
  • Previous history of mental illness.
  • Presence of fever, tuberculosis, tumors, infectious processes, or acute inflammatory processes.
  • Implantation of peacemaker or metallic prosthesis.
  • Use of analgesics within 24 h prior to the experiment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Healthy participant
Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pressure pain threshold (PPT)
Time Frame: 0 to 1 hour
Change in the pressure pain threshold (kPa) recorded after the induced of muscle pain using SWD on the established time point records.
0 to 1 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of changes in pain intensity in direct relation to the experimental model
Time Frame: 0 to 1 hour
Maximum and average pain ratings (0 to 100 score).
0 to 1 hour
Assessment of changes in pain time course in direct relation to the experimental model
Time Frame: 0 to 1 hour
Duration of pain (seconds)
0 to 1 hour
Assessment of changes in functional connectivity in direct relation to the experimental model
Time Frame: 0 to 1 hour
Changes in functional connectivity (FC), assessed through surface electroencephalography (EEG).
0 to 1 hour
Assessment of changes in Pinprick sensitivity
Time Frame: 0 to 1 hour
Pinprick sensitivity (PS) (0 to 100 score).
0 to 1 hour
Assessment of changes in Dynamic tactile sensitivity
Time Frame: 0 to 1 hour
Dynamic tactile sensitivity (DTS) (0 to 100 score).
0 to 1 hour
Assessment of changes in Electrical pain threshold
Time Frame: 0 to 1 hour
Electrical pain threshold (EPT) (mA).
0 to 1 hour
Assessment of changes in Somatosensory evoked potentials
Time Frame: 0 to 1 hour
Somatosensory evoked potentials in response to electrical stimuli (SEP), assessed through EEG. (mV)
0 to 1 hour
Assessment of changes in Movement-related cortical potentials
Time Frame: 0 to 1 hour
Change in Movement-related cortical potentials (MRCP), assessed through EEG.
0 to 1 hour
Assessment of changes in motor responses for upper limb
Time Frame: 0 to 1 hour
Change in precision during motor execution (percentage)
0 to 1 hour
Assessment of changes in motor responses for lower limb
Time Frame: 0 to 1 hour
Change in balance (Centre of pressure)
0 to 1 hour
Assessment of changes in weight loading
Time Frame: 0 to 1 hour
Measured in Kg
0 to 1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: José Biurrun Manresa, PhD, National Scientific and Technical Research Council - Argentina

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 19, 2018

Primary Completion (ACTUAL)

August 29, 2018

Study Completion (ACTUAL)

August 29, 2018

Study Registration Dates

First Submitted

June 5, 2018

First Submitted That Met QC Criteria

June 27, 2018

First Posted (ACTUAL)

June 29, 2018

Study Record Updates

Last Update Posted (ACTUAL)

August 31, 2018

Last Update Submitted That Met QC Criteria

August 29, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data for primary and secondary outcome measures will be made available.

IPD Sharing Time Frame

From first date of publication of journal article.

IPD Sharing Access Criteria

IPD will be provided upon request.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Musculoskeletal Pain

Clinical Trials on Short-wave diathermy

Subscribe